Impact BioMedical Inc.
Price Action
Technical Summary
EMERGING TRENDImpact BioMedical Inc. is attempting to emerge into an uptrend but lacks full moving average alignment. Relative strength is leading (RS Rating: 84), indicating clear outperformance against the broad market. Earnings contraction of 19% provides fundamental context to the price action. Investors should exercise caution due to high volatility (151% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $0.66 | -4.18% | BELOW |
| 50 SMA | $0.59 | +6.90% | ABOVE |
| 100 SMA | $0.54 | +18.05% | ABOVE |
| 150 SMA | $0.54 | +18.10% | ABOVE |
| 200 SMA | $0.56 | +13.35% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is IBO in an uptrend right now?
IBO has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is IBO overbought or oversold?
IBO's RSI (14) is 51. The stock is in neutral territory, neither overbought nor oversold.
Is IBO outperforming the market?
IBO has a Relative Strength (RS) Rating of 84 out of 99. Yes, IBO is a market leader, outperforming 84% of all stocks over the past 12 months.
Where is IBO in its 52-week range?
IBO is trading at $0.64, which is 33% of its 52-week high ($1.95) and 17% above its 52-week low ($0.36).
How volatile is IBO?
IBO has a Beta of 0.12 and 52-week volatility of 151%. It's less volatile than the S&P 500 - generally more stable.